Dr Philip Dormitzer | Vice President and CSO, Viral Vaccines

Dr Philip Dormitzer, Vice President and CSO, Viral Vaccines, Pfizer

Philip R. Dormitzer, M.D., Ph.D. is the Vice President and CSO: Viral Vaccines at Pfizer Vaccine Research and Development. he previously held the position of
Global Head of Research and Vice President at Novartis Influenza Vaccines in Cambridge, Massachusetts.  He is a practicing physician, who is board certified in Internal Medicine.  After studying anthropology at Harvard College and carrying out a field study of the Efe Pygmies in the Ituri Forest of Zaire, he completed his M.D. and Ph.D. in Cancer Biology at Stanford University.  Dr. Dormitzer completed house-staff training in Internal Medicine at Massachusetts General Hospital and a fellowship in the Harvard Combined Infectious Diseases Training Program.  He conducted his fellowship research in the Laboratory of Molecular Medicine, led by Dr. Stephen Harrison.  As an Assistant Professor of Pediatrics at Harvard Medical School, Dr. Dormitzer led a structural virology laboratory.  The Dormitzer group and its collaborators determined the structures of the rotavirus neutralization antigens by NMR spectroscopy, X-ray crystallography, and near atomic resolution electron cryomicroscopy. 
At Novartis, as Senior Project Leader for Viral Vaccine Research, he led global vaccine research projects.  In 2009, these projects included the research component of the Novartis response to the H1N1v influenza pandemic, supporting the development and licensure of three pandemic influenza vaccines in the most rapid vaccine response in history.  As Head of the Viral Advanced Programs Global Team, he coordinated scientific and industrial functions to advance novel viral vaccine projects toward licensure, with a primary focus on an engineered RSV F subunit vaccine candidate, intended for maternal immunization.  As Head of US Vaccines Research, he led approximately 70 scientists based at the Novartis Vaccines Cambridge Research Center in their mission to discover new vaccines, support vaccine development, and sustain licensed vaccines. The team’s technology platforms included structurally engineered antigens, adjuvants that target toll-like receptors, and self-replicating messenger RNA vaccines.  In his current role as Global Head of Research for the newly formed Novartis Influenza Vaccines, he leads a variety of influenza vaccine research efforts. In a BARDA-funded collaboration with the J. Craig Venter Institute and Synthetic Genomics Vaccines, Inc., the Novartis influenza vaccine research team developed a process to synthesize influenza vaccine seed viruses and deployed the technology in response to the H7N9 influenza outbreak in China.


DC Co-conference Day 2 April 4 @ 10:10

Panel: Pfizer’s RSV vaccine program

·         Research background

·         Pre-clinical results and clinical plan

back to speakers